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Clinical PerspectiveWhat Is New?Lowering blood pressure with a low dose of the calcium‐channel blocker nilvadipine does not increase the prevalence of orthostatic hypotension in patients with mild‐to‐moderate Alzheimer disease.This finding was independent of initial blood pressure level or frailty score.What Are the Clinical Implications?This study adds to the discussion on the benefit‐to‐risk ratio of antihypertensive treatment in patients with Alzheimer disease.

 {#jah34118-sec-0009}

With an estimated prevalence of 45%, hypertension is a common comorbidity among patients with Alzheimer disease (AD).[1](#jah34118-bib-0001){ref-type="ref"} Despite this high prevalence, this patient group has not been represented in hypertension trials, leading to uncertainty regarding the benefit‐to‐risk ratio of antihypertensive treatment in these patients.[2](#jah34118-bib-0002){ref-type="ref"} This same discussion concerns frail, older people in general.[3](#jah34118-bib-0003){ref-type="ref"} In the absence of evidence, current guidelines advise being cautious when starting antihypertensive treatment in these groups.[4](#jah34118-bib-0004){ref-type="ref"}, [5](#jah34118-bib-0005){ref-type="ref"}, [6](#jah34118-bib-0006){ref-type="ref"}

A widely voiced concern among physicians is that older people develop orthostatic hypotension (OH) following antihypertensive treatment.[7](#jah34118-bib-0007){ref-type="ref"} The prevalence of OH increases with age,[8](#jah34118-bib-0008){ref-type="ref"} and has been associated with cognitive decline,[9](#jah34118-bib-0009){ref-type="ref"} possibly caused by AD pathology. OH is an independent risk factor for future falls.[10](#jah34118-bib-0010){ref-type="ref"} Therefore, if antihypertensive treatment increases the risk of OH, it could unintentionally lead to increased frailty, institutionalization, or mortality,[11](#jah34118-bib-0011){ref-type="ref"} especially in AD, where cerebral hypoperfusion following OH could accelerate cognitive decline.[12](#jah34118-bib-0012){ref-type="ref"}

Evidence about antihypertensive treatment and OH has mainly emanated from observational studies,[13](#jah34118-bib-0013){ref-type="ref"}, [14](#jah34118-bib-0014){ref-type="ref"}, [15](#jah34118-bib-0015){ref-type="ref"}, [16](#jah34118-bib-0016){ref-type="ref"} while results from randomized clinical trials in healthy older people showed that improved control of blood pressure (BP) did not result in a larger difference between sitting and standing BP.[17](#jah34118-bib-0017){ref-type="ref"}, [18](#jah34118-bib-0018){ref-type="ref"} Whether this also holds for frail populations, such as patients with AD, is currently unknown.

The Nilvad trial was designed to investigate the putative anti‐amyloid properties of the calcium‐channel blocker nilvadipine in mild‐to‐moderate AD.[19](#jah34118-bib-0019){ref-type="ref"} The trial result was negative for cognitive and functional outcomes.[20](#jah34118-bib-0020){ref-type="ref"} However, nilvadipine\'s antihypertensive properties are comparable to other, more commonly used, calcium‐channel blockers.[21](#jah34118-bib-0021){ref-type="ref"}, [22](#jah34118-bib-0022){ref-type="ref"} Therefore, preplanned monitoring of BP throughout the study allowed us to explore the effect of starting an antihypertensive drug on the prevalence of OH in AD. Specifically, the aim of this study was to investigate whether BP lowering with nilvadipine increased the prevalence of OH and OH‐related clinical outcomes in patients with mild‐to‐moderate AD.

Methods {#jah34118-sec-0010}
=======

Because of agreements within the Nilvad consortium, the data that support the findings of this cannot be made available to other researchers for purposes of reproducing the results or replicating the procedure. The corresponding author had full access to all the data in the study and takes responsibility for its integrity and the data analysis.

Study Design {#jah34118-sec-0011}
------------

The Nilvad trial (NCT02017340) was a randomized, double‐blind, placebo‐controlled trial, conducted at 23 sites in 9 European countries. The trial was approved by institutional review boards of each participating country, and all patients as well as relevant caregivers gave written informed consent. A complete description of the trial has been published previously.[19](#jah34118-bib-0019){ref-type="ref"} The main outcome of the trial and any changes made to the study protocol after trial commencement have been reported by Lawlor et al (2018).[20](#jah34118-bib-0020){ref-type="ref"}

Participants {#jah34118-sec-0012}
------------

Patients were recruited from 13 academic and 10 general memory clinics. Patients were eligible if they (1) met the criteria of the National Institute of Neurological and Communicative Disorders and Stroke‐Alzheimer\'s disease and Related Disorders Association[23](#jah34118-bib-0023){ref-type="ref"} for the diagnosis mild‐to‐moderate probable AD, (2) were aged ≥50 years, (3) scored between 12 and 26 on the Mini‐Mental State Examination,[24](#jah34118-bib-0024){ref-type="ref"} (4) had a caregiver available, and (5) were not using a calcium‐channel blocker, β‐blocker, or α‐blocker. For safety reasons, since the trial was not designed to investigate BP lowering, BP had to be between 100 and 159 mm Hg for systolic and between 65 and 99 mm Hg for diastolic BP. Patients using a cholinesterase inhibitor or memantine were eligible if they were on a stable dose for 3 months before screening. The main exclusion criteria were dementia resulting from other causes and the presence of a medical condition that, according to the physician, would preclude participation. A detailed list of inclusion and exclusion criteria is provided in the trial protocol.[19](#jah34118-bib-0019){ref-type="ref"}

Intervention {#jah34118-sec-0013}
------------

The trial used a parallel‐group design with a 1:1 allocation ratio to 8 mg nilvadipine or placebo once daily. Antihypertensive properties of 8 mg of nilvadipine are comparable to 5 mg of amlodipine.[22](#jah34118-bib-0022){ref-type="ref"} Randomization and blinding processes have been described elsewhere.[19](#jah34118-bib-0019){ref-type="ref"} Briefly, randomization was stratified by study site and all study staff was blind to randomization. Study medication was dispensed per 98 capsules at baseline and at every 13‐week follow‐up. Compliance was monitored by collecting the used treatment packs and leftover capsules at each visit. Postrandomization visits occurred at weeks 6, 13, 26, 39, 52, 65, and 78.

Measurements {#jah34118-sec-0014}
------------

At every visit, intermittent BP was measured by qualified study site staff after 5 minutes of rest in the sitting position, and again after 1 and 5 minutes of standing, using a manual sphygmomanometer. Any symptoms noted during standing were recorded. At baseline, the Alzheimer\'s Disease Assessment scale[25](#jah34118-bib-0025){ref-type="ref"} was used to assess cognitive function, the Disability Assessment for Dementia questionnaire[26](#jah34118-bib-0026){ref-type="ref"} was used to assess functional abilities, and the Clinical Dementia Rating scale[27](#jah34118-bib-0027){ref-type="ref"} was used to characterize dementia stage. For patients who had consented to the Nilvad frailty‐substudy, a baseline frailty index was derived.[28](#jah34118-bib-0028){ref-type="ref"}, [29](#jah34118-bib-0029){ref-type="ref"} This index comprised the ratio of deficits present out of 26 possible deficits across multiple domains, resulting in a score between 0 and 1 (see Table [S1](#jah34118-sup-0001){ref-type="supplementary-material"} for a detailed description). We classified patients as fit (index ≤0.10), less fit (0.10\<index≤0.21), or frail (index\>0.21) analogous with the SPRINT (Systolic Blood Pressure Intervention Trial) criteria.[30](#jah34118-bib-0030){ref-type="ref"} Adverse events and concomitant medication use were assessed using structured interviews with patient and caregiver at every visit. Concomitant medication was coded according to the Anatomical Therapeutic Chemical classification system. The study allowed initiation or termination of other antihypertensive medication in case patients developed high or low BP during the study.

Outcomes {#jah34118-sec-0015}
--------

We constructed 3 dichotomous outcomes of OH. Classic OH: a drop of ≥20 mm Hg in systolic blood pressure (SBP) or ≥10 mm Hg in diastolic blood pressure (DBP) after 1 minute of standing compared with sitting BP (consensus criteria);[31](#jah34118-bib-0031){ref-type="ref"} sit‐to‐stand OH: a drop of ≥15 mm Hg in SBP or ≥7 mm Hg in DBP after 1 minute of standing;[32](#jah34118-bib-0032){ref-type="ref"} and symptomatic OH: the presence of symptoms upon standing, irrespective of the drop in BP. This latter category (symptoms suggestive of OH) was included to reduce the risk of missing OH because of false‐negative intermittent BP measurements. In addition, we examined the change in SBP from sitting to standing on a continuous scale (ΔSBP, in mm Hg and %) and the presence of classic OH after 5 minutes of standing, referred to as delayed OH.[13](#jah34118-bib-0013){ref-type="ref"} Clinical outcomes were reported adverse events of fractures, falls, syncope, and dizziness.

Statistical Analyses {#jah34118-sec-0016}
--------------------

The effect of treatment on OH was examined in 2 ways. First, multivariable logistic regression examined the effect of treatment on the proportion of OH at follow‐up, with fixed effects for treatment, baseline ΔSBP (mean‐centered), time and time\*treatment interaction, and random intercepts for patient and study center, to address correlations resulting from repeated measures and center‐specific effects. In case time\*treatment interaction was not significant, it was dropped from the model. Second, we examined the effect of treatment on the number of follow‐up visits in which a patient met criteria for OH, using the total number of visits for that patient as the denominator. Descriptive summaries of these results are presented.

In addition, linear regression was applied to examine the effect of treatment on ΔSBP, with fixed effects for treatment, baseline ΔSBP, time and time\*treatment interaction, and random intercepts for patient and study center. The effect of treatment on the presence of reported clinical outcomes during follow‐up was evaluated with logistic regression.

To test for any potential moderating effects, the following baseline variables and the interaction term for these variables with treatment were added as predictors in the analyses described above: BP status (high: ≥140/90 mm Hg, normal: 130 to 139/70 to 89 mm Hg or low: \<130/70 mm Hg BP at baseline), Mini‐Mental State Examination score, age, frailty index, diabetes mellitus, use of additional antihypertensive medication parallel to the intervention, use of cholinesterase inhibitors, and use of antidepressants.

Analyses were performed on the per protocol population, including only measurements of patients with ≥80% treatment compliance in the 3‐month window before that particular measurement. A complete cases analysis (patients included in all 7 follow‐up visits) was performed as well. Missing values were not imputed. Two‐sided testing and an alpha level of 0.05 were used. Since the analyses were performed post hoc, *P* values should be interpreted with caution and 95% CI of the outcomes that are reported were appropriate. Analyses were performed with SPSS Statistics software version 22.0 and R.[33](#jah34118-bib-0033){ref-type="ref"}

Results {#jah34118-sec-0017}
=======

Characteristics {#jah34118-sec-0018}
---------------

The Nilvad trial was conducted between May 2013 and November 2016. Among 511 randomized patients, 477 (93.3%) were included in the current per protocol analysis (Figure [1](#jah34118-fig-0001){ref-type="fig"}). The proportion of patients who completed all 7 follow‐up visits was 68.3% for nilvadipine and 70.5% for placebo (*P*=0.61). Table [1](#jah34118-tbl-0001){ref-type="table"} shows the baseline demographics and clinical characteristics. Characteristics were the same for the complete cases (Table [S2](#jah34118-sup-0001){ref-type="supplementary-material"}). Reasons to be excluded from the per protocol analysis are detailed in Table [S3](#jah34118-sup-0001){ref-type="supplementary-material"}. The proportion of patients who continuously used an antihypertensive agent parallel to the intervention was 25.4% for nilvadipine and 31.6% for placebo (*P*=0.13). In the nilvadipine group, 5.0% started with an additional antihypertensive drug, whereas 7.9% stopped one. In the placebo group this was 9.3% versus 6.8%, respectively.

![Flow of participants. \*Patients who discontinued the intervention before attending the first follow‐up visit at week 6. ^†^Patients who were not compliant with the study medication (compliance \<80%) during any of the 3‐month windows preceding a follow‐up visit. ^‡^One patient deceased before the first follow‐up visit at week 6 occurred. BP indicates blood pressure; MMSE, Mini‐Mental State Examination score.](JAH3-8-e011938-g001){#jah34118-fig-0001}

###### 

Patient Demographics and Baseline Characteristics

  Characteristics                                                      Placebo (n=237)     Nilvadipine (n=240)
  -------------------------------------------------------------------- ------------------- ---------------------
  Women, no. (%)                                                       138 (58.2)          156 (65.0)
  Age, mean (SD), y                                                    72.0 (7.9)          72.4 (8.6)
  Aged ≥75 y, no. (%)                                                  93 (39.2)           112 (46.7)
  Time since diagnosis of AD, median (IQR), y                          0.9 (0.4--2.3)      1.3 (0.5--2.4)
  Mini‐Mental State Examination score, mean (SD)                       20.5 (3.9)          20.3 (3.8)
  AD Assessment Scale---cognitive subscale, mean (SD)                  34.6 (10.8)         34.5 (10.5)
  Clinical Dementia Rating---sum of boxes, mean (SD)                   5.2 (2.7)           5.4 (2.8)
  Frailty index, median (IQR)[a](#jah34118-note-0004){ref-type="fn"}   0.17 (0.10--0.27)   0.18 (0.11--0.26)
  Fit (index≤ 0.10), no. (%)                                           56 (25.6)           49 (22.3)
  Less fit (0.10\<index≤0.21), no. (%)                                 90 (41.1)           86 (39.1)
  Frail (index\>0.21), no. (%)                                         73 (33.3)           85 (38.6)
  Body mass index, mean (SD), kg/m^2^                                  25.9 (4.4)          25.3 (4.0)
  Sitting systolic blood pressure, mean (SD), mm Hg                    137.2 (14.2)        138.3 (13.7)
  Sitting diastolic blood pressure, mean (SD), mm Hg                   77.2 (8.6)          76.7 (8.7)
  High blood pressure, no. (%)                                         118 (49.8)          137 (57.1)
  Normal blood pressure, no. (%)                                       93 (39.2)           76 (31.7)
  Low blood pressure, no. (%)                                          26 (11.0)           27 (11.3)
  Resting heart rate, mean (SD), beats per min                         70.1 (10.3)         70.7 (10.3)
  Classic orthostatic hypotension, no. (%)                             22 (9.3)            17 (7.1)
  Sit‐to‐stand orthostatic hypotension, no. (%)                        33 (13.9)           38 (15.8)
  Symptomatic orthostatic hypotension, no. (%)                         3 (1.3)             10 (4.2)
  Delayed orthostatic hypotension, no. (%)                             20 (8.4)            14 (5.8)
  Δ Systolic blood pressure, mean (SD), mm Hg                          −0.3 (10.2)         −1.8 (9.6)
  Δ Systolic blood pressure, mean (SD), %                              0.0 (7.3)           −1.1 (7.0)
  Use of medication at study enrollment, no. (%):                                          
  At least 1 antihypertensive medication                               90 (38.0)           80 (33.3)
  ≥2 antihypertensive medications                                      11 (4.6)            8 (3.3)
  Angiotensin II receptor blocker                                      40 (16.9)           33 (13.8)
  Angiotensin‐converting‐enzyme inhibitor                              46 (19.4)           38 (15.8)
  Diuretic                                                             13 (5.5)            18 (7.5)
  Cholinesterase inhibitors                                            212 (89.5)          210 (87.5)
  Memantine                                                            62 (26.2)           64 (26.7)
  Antidepressants                                                      83 (35.0)           89 (37.1)
  Benzodiazepines                                                      12 (5.1)            7 (2.9)
  Antipsychotics                                                       11 (4.6)            11 (4.6)
  Statins                                                              79 (33.3)           84 (35.0)
  Antithrombotics                                                      58 (24.5)           61 (25.4)
  History of cardiovascular disease, no. (%)                           19 (8.0)            19 (7.9)
  Diabetes mellitus, no. (%)                                           8 (3.4)             28 (11.7)

High blood pressure: ≥140/90 mm Hg; normal blood pressure: 130 to 139/70 to 89 mm Hg; low blood pressure: \<130/70 mm Hg. AD indicates Alzheimer disease; IQR, interquartile range; no., number.

n=219 placebo, n=220 nilvadipine (consented to Nilvad frailty‐substudy).

John Wiley & Sons, Ltd

Changes in Sitting Blood Pressure {#jah34118-sec-0019}
---------------------------------

Figure [2](#jah34118-fig-0002){ref-type="fig"} shows the mean sitting SBP and DBP throughout the study. At baseline, sitting SBP and DBP were 138.3±13.7 mm Hg (mean±SD) and 76.7±8.7 mm Hg for nilvadipine and 137.2±14.2 mm Hg and 77.2±8.6 mm Hg for placebo. The proportion of patients with baseline hypertension (BP≥140/90 mm Hg) was 57.1% for nilvadipine and 49.8% for placebo. After 13 weeks of treatment, sitting SBP and DBP had dropped by 7.8±14.0 and 3.9±8.7 mm Hg for nilvadipine and with 0.4±14.1 and 0.8±9.1 mm Hg for placebo (*P*\<0.001 for SBP and DBP). This effect did not differ between those with high, normal, and low BP at baseline (Figure [S1](#jah34118-sup-0001){ref-type="supplementary-material"}), nor between those who did, versus did not, use additional antihypertensive drugs parallel to the intervention (Figure [S2](#jah34118-sup-0001){ref-type="supplementary-material"}). Similar results were observed for the complete cases (Figure [S2](#jah34118-sup-0001){ref-type="supplementary-material"}).

![Effect of treatment on mean sitting SBP and DBP. Mean sitting SBP (**A**) and DBP (**B**) per visit and the number of patients included per visit. After 13 weeks of treatment, sitting SBP and DBP had fallen by −7.8±14.0 and −3.9±8.7 mm Hg for nilvadipine and by −0.4±14.1 and −0.8±9.1 mm Hg for placebo (*P*\<0.001 for SBP and DBP). Error bars indicate SEM. DBP indicates diastolic blood pressure; No., number; SBP, systolic blood pressure.](JAH3-8-e011938-g002){#jah34118-fig-0002}

Orthostatic Hypotension and Clinical Outcomes {#jah34118-sec-0020}
---------------------------------------------

Of 477 patients, 32.9% (n=79) in the nilvadipine group and 34.6% (n=82) in the placebo group met the criteria for classic OH at least once during follow‐up. These proportions were 52.7% and 47.3% for sit‐stand OH, 8.3% and 11.4% for symptomatic OH, and 38.3% and 32.9% for delayed OH, in the nilvadipine and placebo group, respectively. None of the OH outcomes had a significant time\*treatment interaction (classic OH: *P*=0.47, sit‐stand OH: *P*=0.78, symptomatic OH: *P*=0.23, delayed OH: *P*=0.52), and therefore this term was dropped from the models.

Across the 78‐week follow‐up, there was no statistically significant difference between nilvadipine and placebo in the proportion of patients at a study visit meeting the criteria for classic OH (odds ratio \[OR\]=1.1 \[0.8--1.5\], *P*=0.62), sit‐stand OH (OR=1.2 \[0.9--1.5\], *P*=0.15), symptomatic OH (OR=0.8 \[0.3--2.3\], *P*=0.55), or delayed OH (OR=1.2 \[0.9--1.6\], *P*=0.26) (Figure [3](#jah34118-fig-0003){ref-type="fig"}). In addition, there was no clinically relevant effect of nilvadipine on ΔSBP upon standing (in mm Hg: β=−0.8 \[−1.7 to 0.2\], *P=*0.13, in %: β=−0.6 \[−1.3 to 0.2\], *P*=0.12, see Figure [4](#jah34118-fig-0004){ref-type="fig"}). Similar results were observed for complete cases (Table [S4](#jah34118-sup-0001){ref-type="supplementary-material"}).

![Effect of treatment on proportion of patients with orthostatic hypotension. Classic orthostatic hypotension (**A**): drop of ≥20 mm Hg in systolic BP or ≥10 mm Hg in diastolic BP after 1 minute (OR \[95% CI\] =1.1 \[0.8--1.5\], *P=*0.62). Sit‐to‐stand orthostatic hypotension (**B**): of ≥15 mm Hg in systolic BP or ≥7 mm Hg in diastolic BP after 1 minute (OR \[95% CI\] =1.2 \[0.9--1.5\], *P=*0.15). Symptomatic orthostatic hypotension (**C**): presence of symptoms upon standing, irrespective of drop in BP (OR \[95% CI\]=0.8 \[0.3--2.3\], *P=*0.67). Delayed orthostatic hypotension (**D**): presence of classic orthostatic hypotension after 5 minutes of standing (OR \[95% CI\]=1.2 \[0.9--1.6\], *P=*0.15). No. indicates number; OR, odds ratio.](JAH3-8-e011938-g003){#jah34118-fig-0003}

![Effect of treatment on standing minus sitting BP. The figure displays ΔSBP (standing‐sitting SBP) and ΔDBP (standing‐sitting DBP) for nilvadipine and placebo at all visits. As can be seen in the figure, the mean ΔSBP is negative, indicating that standing SBP was lower than sitting SBP. The mean ΔDBP is positive, indicating that standing DBP was higher than sitting DBP. BP indicates blood pressure; DBP, diastolic blood pressure; No., number; SBP, systolic blood pressure.](JAH3-8-e011938-g004){#jah34118-fig-0004}

The proportion of visits where a patient met criteria for OH did not differ between the groups. For nilvadipine and placebo, respectively, these proportions were: 7.7±13.8% and 7.3±11.6% for classic OH, 14.8±18.7% and 12.2±15.5% for sit‐stand OH, 1.8±6.6% and 2.4±8.0% for symptomatic OH, and 8.5±14.3% and 7.3±12.3% for delayed OH.

There were no differences between the groups in the prevalence of OH‐related relevant clinical outcomes of fractures, falls, syncope, or dizziness (Figure [5](#jah34118-fig-0005){ref-type="fig"}).

![Effect of treatment on proportion of reported clinical outcomes related to orthostatic hypotension. Odds ratio results from logistics regression. No. indicates number; OR, odds ratio.](JAH3-8-e011938-g005){#jah34118-fig-0005}

Relationship Between Characteristics and OH {#jah34118-sec-0021}
-------------------------------------------

None of the investigated baseline patient characteristics were significant predictors of OH or moderated the effect of treatment on OH (Table [S5](#jah34118-sup-0001){ref-type="supplementary-material"}). For example, there were no differences between patients with high, normal, or low BP at baseline, or between patients with higher or lower frailty index at baseline. Other baseline characteristics that were investigated included age, Mini‐Mental State Examination score, diabetes mellitus, use of antihypertensives parallel to the intervention, use of antidepressants, and use of cholinesterase inhibitors.

Discussion {#jah34118-sec-0022}
==========

These secondary analyses of a randomized clinical trial investigated the effect of the antihypertensive agent nilvadipine on OH prevalence in patients with mild‐to‐moderate AD. In 477 patients, of whom 53% had grade I hypertension, a 78‐week intervention with 8 mg of nilvadipine (± other antihypertensives) did not result in a significant increase of OH prevalence, determined with intermittent BP measurements while sitting and after 1 minute of standing. Moreover, the number of reported events of fractures, falls, syncope, and dizziness were similar between the groups. None of the predefined baseline characteristics moderated the relationship between nilvadipine and OH, indicating that there were no relevant subgroups for which the results might be different. These characteristics included age, frailty, or the use of other medications that could contribute to OH, such as antidepressants or cholinesterase inhibitors. Previous studies indicated an immediate effect of starting or intensifying antihypertensive treatment on falls and fractures in older people.[34](#jah34118-bib-0034){ref-type="ref"}, [35](#jah34118-bib-0035){ref-type="ref"} We did not see any short‐term effects of our intervention after 6 weeks of treatment (Figure [3](#jah34118-fig-0003){ref-type="fig"}). Although not statistically significant, the upper limits of the CIs of our findings do not completely rule out a small effect of nilvadipine. However, as can be seen in Figures [3](#jah34118-fig-0003){ref-type="fig"} and [4](#jah34118-fig-0004){ref-type="fig"}, the magnitude of such an effect would still not lie within clinically relevant margins.

The antihypertensive properties of nilvadipine are comparable to other, more common dihydropyridine calcium‐channel blockers, such as nifedipine and amlopdipine.[21](#jah34118-bib-0021){ref-type="ref"}, [22](#jah34118-bib-0022){ref-type="ref"} Apart from that, it is known that the main determinant in reducing cardiovascular risk is the amount of BP reduction achieved and not the class of antihypertensive drug.[4](#jah34118-bib-0004){ref-type="ref"}, [36](#jah34118-bib-0036){ref-type="ref"}, [37](#jah34118-bib-0037){ref-type="ref"} The BP reduction achieved in our study was moderate, but still falls within the range of BP reductions observed with other antihypertensives that successfully reduced cardiovascular events and mortality.[38](#jah34118-bib-0038){ref-type="ref"}

It can be questioned whether the absence of a drug class effect in reducing cardiovascular risk is also applicable to the risk of OH. For β‐blockers, treatment has been associated with an increased risk of OH,[39](#jah34118-bib-0039){ref-type="ref"}, [40](#jah34118-bib-0040){ref-type="ref"} which might be explained by their sympatholytic effects interfering with baroreflex‐mediated BP recovery.[14](#jah34118-bib-0014){ref-type="ref"}, [15](#jah34118-bib-0015){ref-type="ref"}, [40](#jah34118-bib-0040){ref-type="ref"} However, the efficacy and safety profile of β‐blockers as first‐line treatment of hypertension (in older patients) has already been questioned for other reasons.[4](#jah34118-bib-0004){ref-type="ref"}, [41](#jah34118-bib-0041){ref-type="ref"} For the remaining drug classes, a cross‐sectional analysis from the TILDA (The Irish Longitudinal Study on Ageing) study found no differences in OH risk between single therapy with calcium‐channel blockers, renin‐angiotensin‐aldosterone‐system blockers, and diuretics, arguing against a drug class effect other than β‐blockers and thus favoring the extrapolation of nilvadipine to antihypertensive treatment in general.[40](#jah34118-bib-0040){ref-type="ref"}, [42](#jah34118-bib-0042){ref-type="ref"}

The hypothesis for a link between antihypertensive treatment and OH in older people has mainly emanated from findings of observational studies.[13](#jah34118-bib-0013){ref-type="ref"} Evidence from randomized clinical trials is limited, especially in populations with cognitive impairment.[2](#jah34118-bib-0002){ref-type="ref"} The ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial (Type II diabetes mellitus, aged 62±7 years) and AASK (the African American Study of Kidney Disease and Hypertension) (black patients with kidney disease and hypertension, aged 54±10 years) trial found no effect of antihypertensive treatment on OH.[43](#jah34118-bib-0043){ref-type="ref"}, [44](#jah34118-bib-0044){ref-type="ref"} Subgroup analyses from SPRINT in people aged ≥75 years showed no difference in prevalence of OH, falls, or syncope between the intensive BP‐lowering group and the standard treatment group.[17](#jah34118-bib-0017){ref-type="ref"} Also HYVET (the Hypertension in the Very Elderly Trial) (aged ≥80 years) did not report a difference between the intervention (indapamide ± perindopril) and placebo group in sitting minus standing BP.[18](#jah34118-bib-0018){ref-type="ref"} However, it has previously been recognized that participants of both SPRINT and HYVET were relatively fit and healthy and had no cognitive impairment or dementia,[3](#jah34118-bib-0003){ref-type="ref"}, [45](#jah34118-bib-0045){ref-type="ref"} hampering the extrapolation of their results to a more frail population. This is an important limitation, because frailty can decrease the ability to adequately respond to challenges (ie, antihypertensive treatment) and increase the risks of corresponding adverse outcomes (ie, OH).[28](#jah34118-bib-0028){ref-type="ref"}

A slightly more vulnerable population was studied in the DANTE (Discontinuation of Antihypertensive Treatment in Elderly People) trial, which assessed the effect of deprescribing antihypertensive treatment in people aged ≥75 years with mild cognitive impairment.[46](#jah34118-bib-0046){ref-type="ref"} Subgroup analyses found no convincing evidence that the prevalence of OH was reduced when antihypertensive medication was stopped and SBP increased by 4.3 mm Hg.[47](#jah34118-bib-0047){ref-type="ref"} Our study results are in line with SPRINT, HYVET, and DANTE, but now in a population with mild‐to‐moderate AD, a group that has been excluded from previous trials. Although we recognize that cognitive impairment is just one, albeit a very dominant one, dimension of frailty,[28](#jah34118-bib-0028){ref-type="ref"} this study contributes to understanding the effect of antihypertensive treatment on OH in a vulnerable population.

It has been suggested that OH in AD may be related to autonomic dysfunction instead of cardiovascular disease.[48](#jah34118-bib-0048){ref-type="ref"} However, evidence for this is limited, and may have been biased by misclassification of Lewy body dementia as AD.[49](#jah34118-bib-0049){ref-type="ref"} We recently demonstrated that baroreflex sensitivity was not impaired in mild‐to‐moderate AD, which would also argue against autonomic impairment in AD.[50](#jah34118-bib-0050){ref-type="ref"}

Strengths and Limitations {#jah34118-sec-0023}
-------------------------

Strengths of this study are the thorough design, standardized procedures, 100% monitoring, and low attrition rate, adding to a high internal validity. Although these secondary analyses were not prespecified in the trial protocol, careful monitoring of BP, OH, and OH‐related outcomes was a preplanned part of the study for safety reasons. Like any clinical trial, we are limited by the inclusion and exclusion criteria. This, for example, resulted in a relatively younger sample of AD patients compared with the general AD population, where \>80% is older than 75 years. However, certain generalizability of our findings is still supported by the heterogeneity of baseline cognitive scores, frailty levels, age, and the fact that recruitment took place at both academic and general hospitals. Extrapolation to clinical AD populations is also aided by the fact that no biomarker evidence for AD (such as cerebrospinal fluid or positron emission tomography--amyloid imaging) was required, as such a requirement may lead to considerable selection bias (towards younger, less frail AD patients, and patients seen at tertiary centers). According to the recent Research Framework for AD of the National Institute on Aging and the Alzheimer\'s Association, our study population would be classified as "Alzheimer clinical syndrome."[51](#jah34118-bib-0051){ref-type="ref"}

Patients were allowed to use concomitant medication (provided that it did not interfere with nilvadipine), including cholinesterase inhibitors and/or memantine and antidepressants. This enhances generalizability, because concomitant use of these drugs (for example, antidepressants) is not only common but also increases the risk of falls or OH.[52](#jah34118-bib-0052){ref-type="ref"}, [53](#jah34118-bib-0053){ref-type="ref"}

Baseline hypertension was not a requirement for inclusion, resulting in a study population that does not consist merely of patients who would normally qualify for antihypertensive treatment. However, sensitivity analyses showed the same result in those with baseline hypertension. Moreover, the absence of adverse effects at lower entry BP levels only strengthens our findings and attunes with the latest hypertension guidelines.[4](#jah34118-bib-0004){ref-type="ref"}

External validity is limited by the exclusion of patients with severe hypertension (≥160/99 mm Hg). Also, baseline prevalence of OH was lower (8%) than previously reported in AD,[9](#jah34118-bib-0009){ref-type="ref"} which might be an illustration of inclusion bias toward healthier patients. This is, however, not supported by the distribution of the cognitive scores and frailty.

We measured BP using intermittent BP measurements with patients sitting and 1 minute after they were standing. Although this deviates from the 3‐minute guideline recommendation,[54](#jah34118-bib-0054){ref-type="ref"} it was recently suggested that measuring after 1 minute correlates better with clinical outcomes.[55](#jah34118-bib-0055){ref-type="ref"} Our choice to measure BP while patients were sitting rather than supine may have underestimated the prevalence of OH, because of reduced gravitational venous pooling. However, using the proposed diagnostic cut‐off for sit‐to‐stand OH measurements resulted in similar findings.[32](#jah34118-bib-0032){ref-type="ref"} Finally, the reliability of reporting adverse event and symptoms upon standing might be low in a population with cognitive impairment, possibly leading to underreporting. These concerns were in part mitigated, however, because we conducted regular semistructured interviews with the patient\'s caregiver.

Perspectives {#jah34118-sec-0024}
------------

The implications of our findings are 2‐fold. First, our study adds to the discussion on the benefit‐to‐risk ratio of the use of antihypertensive medication in AD,[56](#jah34118-bib-0056){ref-type="ref"} by providing hitherto missing evidence that OH risk is not exacerbated by treatment. Although more evidence is required, some patients with mild‐to‐moderate AD may still benefit from antihypertensive treatment. For instance, the average estimated survival after AD diagnosis is 3 to 9 years,[57](#jah34118-bib-0057){ref-type="ref"} while positive effects of antihypertensive treatment in the elderly already become apparent after 1 year of treatment.[17](#jah34118-bib-0017){ref-type="ref"}, [18](#jah34118-bib-0018){ref-type="ref"} Furthermore, comorbidities, including cardiovascular and cerebrovascular events, can have detrimental effects on progression of AD, and are 1 of the major causes of death in AD.[58](#jah34118-bib-0058){ref-type="ref"}, [59](#jah34118-bib-0059){ref-type="ref"}, [60](#jah34118-bib-0060){ref-type="ref"} Thus, withholding treatment in a patient with AD because of an overestimated fear of OH might negatively affect patient outcomes. Instead, we advocate that decisions regarding antihypertensive treatment should always be tailored to patient\'s preferences and physical and mental status.[56](#jah34118-bib-0056){ref-type="ref"}

Another implication of our findings is that they add to the complex debate on the use of antihypertensive medication in vulnerable older people,[6](#jah34118-bib-0006){ref-type="ref"} of which this AD population is an important example. It is a persistent belief among many physicians that treating older people with antihypertensive medication would do more harm than good.[7](#jah34118-bib-0007){ref-type="ref"} The current study has recruited, to date, the most vulnerable population and found that treatment with a low‐dose calcium‐channel blocker led to an effective, moderate BP reduction without causing harm in the sense of OH, or OH‐related adverse outcomes such as falls or fractures.

Conclusions {#jah34118-sec-0025}
===========

In patients with mild‐to‐moderate AD, with or without hypertension, 78‐week treatment with 8 mg of the calcium‐channel blocker nilvadipine did not significantly increase the risk of OH, fractures, falls, syncope, and dizziness. We provide evidence that starting or adding a low dose of antihypertensive treatment is safe with respect to OH and clinical outcomes. Trials that are primarily designed to investigate patient‐relevant beneficial as well as adverse outcomes of antihypertensive treatment are required to elicit the full benefit‐to‐risk balance in this quickly growing patient group.

Appendix {#jah34118-sec-0026}
========

The Nilvad Study Group includes, in addition to the authors in the by‐line: Ricardo Segurado, CSTAR and School of Public Health, Physiotherapy and Sport Science, University College Dublin (UCD), Dublin, Ireland; Sean Kennelly, Department of Age Related Healthcare, Tallaght Hospital, Dublin 24 and Department of Medical Gerontology, Trinity College Dublin; Robert Howard, Division of Psychiatry, University College London and King\'s College London; Florence Pasquier, CHU Lille, Univ. Lille, DISTALZ Laboratory of Excellence, F‐59000 Lille, France; Anne Börjesson‐Hanson, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg; Magda Tsolaki, Papanikolaou General Hospital of Thessaloniki, Greece; Ugo Lucca, Laboratory of Geriatric Neuropsychiatry, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; D. William Molloy, University College Cork Centre for Gerontology and Rehabilitation, Cork, Ireland; Robert Coen, Mercer\'s Institute for Research on Ageing, St. James\'s Hospital, Dublin, Ireland; Matthias W. Riepe, Department of Geriatrics and Old Age Psychiatry, Psychiatry II, Ulm University at BKH Günzburg, Germany; János Kálmán, Department of Psychiatry, University of Szeged, Hungary; Rose Anne Kenny, Department of Medical Gerontology, Trinity College Dublin (TCD), Dublin, Ireland; Fiona Cregg, Department of Medical Gerontology, Trinity College Dublin (TCD), Dublin, Ireland; Sarah O\'Dwyer, Mercer\'s Institute for Research on Ageing, St. James\'s Hospital, Dublin, Ireland; Cathal Walsh, Health Research Institute and MACSI, Department of Mathematics and Statistics, University of Limerick, Ireland; Jessica Adams, Department of Old Age Psychiatry, King\'s College London; Rita Banzi, Laboratory of Geriatric Neuropsychiatry, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Laetitia Breuilh, CHU Lille, Univ. Lille, DISTALZ Laboratory of Excellence, F‐59000 Lille, France; Leslie Daly, CSTAR and School of Public Health, Physiotherapy and Sport Science, University College Dublin (UCD), Dublin, Ireland; Suzanne Hendrix, Pentara Corporation, 2180 Claybourne Avenue, Salt Lake City, UT 84109, USA; Paul Aisen, Department of Neurology, University of Southern California; Siobhan Gaynor, Molecular Medicine Ireland (MMI), Dublin, Ireland; Ali Sheikhi, Health Research Institute and MACSI, Department of Mathematics and Statistics, University of Limerick, Ireland; Diana G. Taekema, Department of Geriatric Medicine, Rijnstate Hospital, Arnhem, The Netherlands; Frans R. Verhey, Department of Psychiatry and Neuropsychology, School of Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, The Netherlands; Raffaello Nemni, IRCCS Don Gnocchi Foundation‐University of Milan, Italy; Flavio Nobili, Dept. of Neuroscience (DINOGMI), University of Genoa, and IRCCS AOU Polyclinic, Hospital San Martino, Genoa, Italy; Massimo Franceschi, Neurology Department, Multimedica, Castellanza, Italy; Giovanni Frisoni, Centro San Giovanni di Dio---IRCCS Fatebenefratelli, Brescia, Italy; Orazio Zanetti, Centro San Giovanni di Dio---IRCCS Fatebenefratelli, Brescia, Italy; Anastasia Konsta, Aristotle University of Thessaloniki (AUTH), First Psychiatric Department, Papageorgiou General Hospital, Greece; Orologas Anastasios, Ahepa University General Hospital of Thessaloniki, Greece; Styliani Nenopoulou, Papanikolaou General Hospital of Thessaloniki, Greece; Fani Tsolaki‐Tagaraki, Papanikolaou General Hospital of Thessaloniki, Greece; Magdolna Pakaski, Department of Psychiatry, University of Szeged, Hungary; Olivier Dereeper, Centre Hospitalier de Calais, France; Vincent de la Sayette, Centre Hospitalier Universitaire de Caen, France; Olivier Sénéchal, Centre Hospitalier de Lens, France; Isabelle Lavenu, Centre Hospitalier de Béthune, France; Agnès Devendeville, Centre Hospitalier Universitaire d\'Amiens, France; Gauthier Calais, Groupement des Hôpitaux de l\'Institut Catholique de Lille (GHICL), France; Fiona Crawford, Archer Pharmaceuticals Inc., 2040 Whitfield Avenue, Sarasota, Florida, USA and Roskamp Institute, Sarasota, Florida, USA; Michael Mullan, Archer Pharmaceuticals Inc., 2040 Whitfield Avenue, Sarasota, Florida, USA and Roskamp Institute, Sarasota, Florida, USA; Pauline Aalten, Ph.D., Department of Psychiatry and Neuropsychology, School of Mental Health and Neurosciences, Alzheimer Center Limburg, Maastricht University, Maastricht, The Netherlands; Maria A. Berglund, R.N., Sahlgrenska University Hospital, Gotheburg, Sweden; Daan L. K. de Jong, M.Sc., Radboud university medical center, Donders Institute for Brain Cognition and Behaviour, Department of Geriatric Medicine, Radboud Alzheimer Center, Nijmegen, The Netherlands; Olivier Godefroy, M.D., Ph.D., Centre Hospitalier Universitaire d\'Amiens, France; Siobhan Hutchinson, M.D., St. James\'s Hospital, Dublin, Ireland; Aikaterini Ioannou, M.D. 1st Department of Neurology, Ahepa University General Hospital, Aristotle University of Thessaloniki, Greece; Michael Jonsson, M.D., Ph.D., Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden; Annette Kent, Ph.D., Trinity College Dublin (TCD), Dublin, Ireland; Jürgen Kern, M.D., Ph.D., Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden; Petros Nemtsas, M.D., Ph.D., 1st Department of Neurology, Ahepa University General Hospital, Aristotle University of Thessaloniki, Greece; Minoa‐Kalliopi Panidou, B.Sc., M.A., 1st Department of Neurology, Ahepa University General Hospital, Aristotle University of Thessaloniki, Greece; Laila Abdullah, Ph.D., Archer Pharmaceuticals Inc, 2040 Whitfield Avenue, Sarasota, Florida, USA; Daniel Paris, Ph.D., Archer Pharmaceuticals Inc, 2040 Whitfield Avenue, Sarasota, Florida, USA; Gerrita J. van Spijker, M.Sc., Radboud university medical center, Donders Institute for Brain Cognition and Behaviour, Department of Geriatric Medicine, Radboud Alzheimer Center, Nijmegen, The Netherlands; Martha Spiliotou, M.D., Ph.D., 1st Department of Neurology, Ahepa University General Hospital, Aristotle University of Thessaloniki, Greece; Georgia Thomoglou, B.Sc., 1st Department of Neurology, Ahepa University General Hospital, Aristotle University of Thessaloniki, Greece; Anders Wallin, M.D., Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden.
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**Table S1.** Composition of the Frailty Index

**Table S2.** Patient Demographics and Characteristics for Complete Cases

**Table S3.** Inclusions and Exclusions From the Per Protocol Analysis Per Follow‐Up Visit

**Table S4.** Effect of Treatment on Orthostatic Hypotension

**Table S5.** Results From Regression Models Estimating the Effect of Treatment and Moderators on Orthostatic Hypotension

**Figure S1.** Effect of treatment on sitting systolic and diastolic BP in patients with high, normal, and low BP at baseline. Mean sitting systolic (**A** through **C**) and diastolic (**D** through **F**) BP per visit in patients with high (≥140/90 mm Hg), normal (130--139/70--89 mm Hg), and low (\<130/70 mm Hg) baseline BP for nilvadipine (dashed line) and placebo (solid line). After 13 weeks of treatment, mean difference between nilvadipine and placebo was −8.0/−3.5 mm Hg, −4.7/−1.7 mm Hg, and −7.6/−3.5 mm Hg for high‐, normal‐, and low‐BP, respectively. No interaction was present between treatment and baseline BP (*P=*0.45 for systolic and *P=*0.55 for diastolic BP), assessed after 13 weeks. Error bars indicate SEM. BP indicates blood pressure.

**Figure S2.** Effect of treatment on sitting systolic and diastolic BP for complete cases and for use of additional antihypertensive drugs parallel to the intervention. Mean sitting systolic (**A** through **C**) and diastolic (**D** through **F**) BP per visit in the complete cases (**A**,**D**) and in nonusers (**B**,**D**) and users (**C**,**F**) of additional antihypertensive drugs parallel to the intervention for nilvadipine (dashed line) and placebo (solid line). After 13 weeks of treatment, mean difference between nilvadipine and placebo was −7.4/−3.1 mm Hg, −8.0/−3.9 mm Hg, and −6.1/−1.7 mm Hg for complete cases, nonusers, and users, respectively. No interaction was present between treatment and use of antihypertensive drugs (*P*=0.48 for systolic BP and *P*=0.20 for diastolic BP). Error bars indicate SEM. AHD indicates antihypertensive drugs; BP, blood pressure.
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